Table A1.
Trends in antimicrobial use in pharmacies according to the medical institutions from which a high proportion of prescriptions were received.
| Hospital | Clinic | |||||||
|---|---|---|---|---|---|---|---|---|
| Jan-19 DPM, Median (IQR) |
Jun-19 DPM, Median (IQR) |
Jan-21 DPM, Median (IQR) |
Jun-21 DPM, Median (IQR) |
Jan-19 DPM, Median (IQR) |
Jun-19 DPM, Median (IQR) |
Jan-21 DPM, Median (IQR) |
Jun-21 DPM, Median (IQR) |
|
| J01AA Tetracyclines | 0 (0–15.6) |
0 (0–19.1) |
0 (0–17.9) |
0 (0–21.3) |
0 (0–7.0) |
0 (0–7.6) |
0 (0–7.7) |
0 (0–9.7) |
| J01BA Amphenicols | 0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
| J01CA Penicillins with extended spectrum | 10.7 (1.6–25.6) |
11.8 (1.9–26.8) |
11.8 (2.8–27.2) |
13.0 (2.9–25.9) |
3.7 (0–14.6) |
4.1 (0–16.3) |
3.9 (0–14.9) |
4.2 (0–13.6) |
| J01CE Beta-lactamase sensitive penicillins | 0 (0, 0) |
0 (0, 0) |
0 (0, 0) |
0 (0, 0) |
0 (0, 0) |
0 (0, 0) |
0 (0, 0) |
0 (0, 0) |
| J01CR Combinations of penicillins, incl. beta-lactamase inhibitors | 4.74 (0–10.9) |
5.4 (0–12.9) |
4.4 (0–13.3) |
5.1 (0–13.4) |
0 (0–4.3) |
0 (0–5.6) |
0 (0–4.3) |
0 (0–4.9) |
| J01DB First-generation cephalosporins | 0 (0–0.2) |
0 (0–1.5) |
0 (0–3.0) |
0 (0–3.0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
| J01DC Second-generation cephalosporins | 0 (0–8.2) |
0 (0–9.6) |
0 (0–9.9) |
1.6 (0–13.9) |
0 (0–1.6) |
0 (0–2.5) |
0 (0–2.6) |
0 (0–3.1) |
| J01DD Third-generation cephalosporins | 33.4 (16.7–55.5) |
28.9 (13.7–51.1) |
20.8 (8.6–37.0) |
19.2 (7.8–37.4) |
40.8 (17.0–90.6) |
40.0 (16.1–84.1) |
25.7 (9.9–59.4) |
25.1 (9.0–56.7) |
| J01DH Carbapenems | 0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
| J01DI Other cephalosporins and penems | 0 (0–1.6) |
0 (0–1.4) |
0 (0–0) |
0 (0–1.1) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
| J01EB Short-acting sulfonamides | 0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
| J01EC Intermediate-acting sulfonamides | 0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
| J01ED Long-acting sulfonamides | 0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
| J01EE Combinations of sulfonamides and trimethoprim, including derivatives | 4.1 (0–18.5) |
4.74 (0–21.3) |
3.8 (0–22.5) |
2.9 (0–18.7) |
0 (0–3.1) |
0 (0–3.4) |
0 (0–4.5) |
0 (0–4.0) |
| J01FA Macrolides | 52.0 (20.4–108.0) |
47.4 (18.9–97.1) |
37.9 (10.3–97.9) |
36.0 (8.7–92.9) |
46.3 (16.1–115.0) |
39.7 (13.3–100.3) |
27.3 (5.7–66.6) |
23.1 (4.8–56.4) |
| J01FF Lincosamides | 0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
| J01MA Quinolones | 57.1 (27.3–96.4) |
51.5 (23.9–91.2) |
45.6 (18.3–82.8) |
41.5 (17.4–73.2) |
51.0 (18.2–111.7) |
45.2 (16.0–104.8) |
32.9 (10.6–74.7) |
31.5 (9.5–65.0) |
| J01MB Other quinolones | 0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
| J01XX Other antibacterials | 0 (0–1.6) |
0 (0–2.0) |
0 (0–1.0) |
0 (0–1.5) |
0 (0–1.9) |
0 (0–2.5) |
0 (0–0.7) |
0 (0–1.3) |
Values represent the median (interquartile range) of DPM (defined daily doses/1000 prescriptions/month).